ACRVNasdaqPharmaceutical PreparationsFiscal year ends December 31
Acrivon Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.69+0.05 (+3.05%)
Close on Oct 19, 2026
- Market cap
- $70.71M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.12 (−6.63%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $70.71M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.82
- Dividend yield
- –
- Free cash flow yield
- -90.70%
Fundamentals
- Net income
- -$74.23M
- EPS, diluted
- -$1.88
- Free cash flow
- -$64.14M
- Book value per share
- $2.07
- Diluted shares
- 42M
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Operating income
-$78.37M
Net income
-$74.23M
EPS, diluted
-$1.88
Free cash flow
-$64.14M
Reported periodTrailing twelve months